GlassScriptPhysician profile
Gordon Byrnes
NPI 1295709699
$2,810.75
in general payments reported to CMS, 2019-2025
15 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $24.89 · 2021: $95.22 · 2022: $254 · 2023: $493 · 2024: $782 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $725.19 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $689.86 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $322.39 | 2021-2025 | Vabysmo |
| Abbvie INC. | $246.81 | 2023-2025 | Ozurdex |
| Astellas Pharma US INC | $223.46 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $173.95 | 2023-2025 | Xipere |
| Novartis Pharmaceuticals Corporation | $82.26 | 2019 | |
| Allergan, INC. | $77.18 | 2019-2021 | |
| Harrow Eye, LLC | $68.68 | 2025 | Iheezo |
| Vertos Medical, INC. | $52.25 | 2024 | Mild Device Kit |
| Amgen INC. | $46.86 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $32.29 | 2025 | Iluvien |
| Alimera Sciences, INC. | $27.52 | 2023 | Iluvien |
| Coherus Oncology, INC. | $26.34 | 2023 | |
| Shire North American Group INC | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Byrnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.